Voyager Therapeutics Inc

For the period ended Mar 31, 2024. Filed May 13, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 13, 2024

VYGR$1.83-8.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) Income

(amounts in thousands, except share and per share data)


· · Three Months Ended ·
· · March 31,
· 2024 · 2023
Collaboration revenue	$19,516	$150,480
Operating expenses:
Research and development	27,092	18,568
General and administrative	8,607	9,028
Total operating expenses	35,699	27,596
Operating (loss) income	(16,183)	122,884
Other income:
Interest income	4,867	1,864
Total other income	4,867	1,864
(Loss) income before income taxes	(11,316)	124,748
Income tax provision	14	704
Net (loss) income	$(11,330)	$124,044
Other comprehensive (loss) income:
Net unrealized (loss) gain on available-for-sale securities	(458)	87
Total other comprehensive (loss) income	(458)	87
Comprehensive (loss) income	$(11,788)	$124,131
Net (loss) income per share, basic	$(0.20)	$3.05
Net (loss) income per share, diluted	$(0.20)	$2.94
Weighted-average common shares outstanding, basic	57,117,046	40,632,087
Weighted-average common shares outstanding, diluted	57,117,046	42,161,326

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.